Inogen EVP R&D & Chief Medical Officer Stanislav Glezer to depart by May 3, 2024

Inogen Inc

Mutual separation of Dr. Stanislav Glezer, EVP R&D and Chief Medical Officer, effective on or before May 3, 2024.
Company expects to enter a separation agreement with benefits consistent with his existing 2021 severance agreement.
No successor named; disclosure of separation agreement terms to be filed later.
Glezer was responsible for R&D and clinical strategy; departure leaves a key leadership gap.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stanislav Glezer

Executive Vice President, R&D and Chief Medical Officer

INGN · Inogen Inc

Effective: 2024-05-03
Filed: April 15, 2024, 7:59 PM ET

On April 11, 2024, Inogen, Inc. (the “Company”) and Dr. Stanislav Glezer, Executive Vice President, R&D and Chief Medical Officer of the Company, mutually determined that Dr. Glezer would separate from the Company on or before May 3, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Stanislav Glezer departed as Executive Vice President, R&D and Chief Medical Officer at Inogen Inc.

Action: separated
Role: Executive Vice President, R&D and Chief Medical Officer

Exact text from the filing

On April 11, 2024, Inogen, Inc. (the “Company”) and Dr. Stanislav Glezer, Executive Vice President, R&D and Chief Medical Officer of the Company, mutually determined that Dr. Glezer would separate from the Company on or before May 3, 2024.

View on SEC.gov

Inogen Inc filing history →

Source: SEC EDGAR

accession 0000950170-24-044416

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.